Klaricid-OD: Main Uses and Therapeutic Support

Klaricid-OD is applied across domains where additional symptomatic support is needed, addressing symptoms related to systemic imbalance and localized discomfort. This medication is relevant for use in conditions characterized by periods of heightened symptoms such as certain lower respiratory tract conditions, sinus conditions, and skin and soft tissue conditions. It is also used in conditions presenting with systemic or localized discomfort, such as those associated with H. pylori (stomach ulcers).

Key Symptomatic Domains

The medicine is often used when symptoms intensify and supportive relief is needed, particularly in clinical settings involving distressing symptoms like persistent cough, fever, facial pain, or localized skin discomfort. Using this medication supports the patient during difficult episodes by easing the overall symptom burden and may assist with maintaining functional stability when symptoms become more noticeable. It contributes to improved comfort during symptomatic periods and assists with easing the overall symptom load across different condition categories.

Quick Fact

Quick Fact: Supportive management for Heightened Respiratory Discomfort Klaricid-OD is commonly used to help manage symptoms related to inflammatory or irritative states that may cause chest congestion and difficulty breathing.

Regulatory References

1. U.S. National Institutes of Health (NIH) DailyMed

Klaricid-OD (Clarithromycin Extended-Release) has strict eligibility requirements defined by regulatory agencies. Use is contraindicated and must be avoided in populations with a known hypersensitivity to clarithromycin or any macrolide antibacterial drug. Absolute non-eligibility also applies to patients with a history of QT prolongation or ventricular cardiac arrhythmia, as well as those with uncorrected electrolyte imbalances like hypokalemia or hypomagnesemia. The medicine is also strictly prohibited for patients taking certain concomitant medications, including Simvastatin and Cisapride.

Eligibility Constraints

• Age Restrictions: The extended-release tablet is indicated only for use in adults for its approved conditions. Pediatric use is not established for this formulation.
• Organ Function: Use is contraindicated in cases of severe hepatic failure combined with renal impairment. Patients with severe renal impairment (creatinine clearance less than 30 mL/min) require caution and special consideration.
• Reproductive Status: Use is not recommended in pregnant women due to the potential for fetal harm, and use during lactation requires balancing potential risks and benefits to the infant.

Klaricid-OD Interactions with other medicines and products

The active ingredient in Klaricid-OD, Clarithromycin, is officially documented as an inhibitor of the metabolic enzyme Cytochrome P450 3A4 (CYP3A4) and the efflux transporter P-glycoprotein (P-gp). This characteristic defines the majority of its clinically significant interactions, as noted in official prescribing information.

Formal Contraindicated Combinations

Certain medicinal products are formally prohibited for co-administration with Klaricid-OD due to the documented risk of serious adverse reactions, including QT prolongation and severe muscle toxicity (rhabdomyolysis):

• HMG-CoA Reductase Inhibitors: Lovastatin, Simvastatin
• Ergot Alkaloids: Ergotamine, Dihydroergotamine
• Other Agents: Cisapride, Pimozide, Astemizole, Terfenadine, Lomitapide, Lurasidone, Oral Midazolam, Domperidone

Documented Exposure Modifications

Co-administration with Klaricid-OD can lead to increased plasma levels of several medicines, including Digoxin, Theophylline, and Carbamazepine, requiring careful monitoring. Official documents also note that the use of Warfarin with Clarithromycin necessitates monitoring due to increased anticoagulant effects. Conversely, the concentration of Zidovudine may be reduced if not administered separately.

Other Official Restrictions

Inhibition of Essential Bacterial Protein Synthesis

This core mechanistic domain is defined by the drug's high-affinity binding to the 23S ribosomal RNA within the bacterial 50S ribosomal subunit. By physically blocking the peptide exit tunnel , Clarithromycin disrupts the crucial protein synthesis pathway, thereby preventing the bacteria from creating the proteins required for growth and division. The resulting cellular consequence is the halt of bacterial protein synthesis, leading to failure of growth and replication.

️ Secondary Modulation of Host Inflammatory Pathways

Clarithromycin also engages a secondary, non-antimicrobial mechanism by influencing cellular signaling. This mechanism is associated with the modulation of pro-inflammatory mediator production (e.g., IL-8). This action is a pharmacodynamic effect on host processes, independent of the direct antimicrobial action.

️ Understanding Mechanistic Resistance

This domain addresses the biological constraints on the drug's function arising from counter-mechanisms in the target bacteria. These mechanisms include ribosomal methylation (altering the 23S rRNA binding site), gene mutations that reduce affinity, and the activation of efflux pumps that actively expel the drug. These processes result in a reduction of Clarithromycin's binding affinity or its intracellular concentration at the 50S ribosomal subunit.

How to Use Klaricid-OD

The administration of Klaricid-OD (clarithromycin extended-release) is designed to ensure the medication functions as intended. This product is an oral medication and is administered only as a film-coated, extended-release tablet.

Official Dosing and Frequency

Klaricid-OD is characterized by its once-daily (q24h) dosing pattern, which is central to its therapeutic use. The standard dose for most adult indications, such as community-acquired pneumonia and acute sinusitis, is 1,000 mg per day. The overall treatment duration typically requires a course of either 7 days or 14 days, depending on the condition addressed.

Administration Conditions

To ensure proper absorption, the tablet is taken with food. This is required for the medication to achieve the necessary bioavailability. A critical procedural condition is that the extended-release tablet must be swallowed whole; it must not be crushed, broken, or chewed. Manipulation of the tablet destroys the sustained-release mechanism, leading to rapid, potentially excessive drug release.

Population-Specific Use Restrictions

The use of the extended-release form is subject to specific restrictions for certain patient groups. Klaricid-OD is not recommended for use in children under 12 years of age. Furthermore, it is generally not recommended for patients with severe renal impairment (creatinine clearance less than 30 mL/min) because the fixed-dose 500 mg tablet cannot be split to achieve the necessary reduced dose.

Research Evidence / Overview of Studies for Klaricid-OD

Evidence for Use in Lower Respiratory Tract Conditions

The evidence base includes multiple Randomized Controlled Trials (RCTs) and comparative studies, where researchers observed patterns in populations over defined time intervals. Research was conducted during periods of increased symptom activity for conditions such as community-acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB). These trials often compared the once-daily extended-release tablet against the standard immediate-release version, as well as against other existing antibiotics.

Studies exploring long-term outcomes, such as the full durability of the effect or the prevention of future episodes, indicate that evidence is limited, as trials focused on short-term monitoring. Research described patterns related to cardiovascular events and mortality that were observed in the studied populations during the long-term monitoring. This evidence contributes to the broader evidence landscape for the drug class, but research provides limited context for long-term outcomes specific to the extended-release formulation.

Evidence for Use in Upper Respiratory Tract and Sinus Conditions

This medicine was studied for its use in conditions involving periods of heightened symptoms, including acute maxillary sinusitis and related infections like pharyngitis. The evidence base includes both Randomized Controlled Trials (RCTs) and subsequent post-marketing observational studies designed to assess short-term symptom patterns.

Studies monitored outcomes related to physical discomfort and physiological strain, alongside objective assessments, such as radiographic success for sinusitis. Findings described patterns observed in the studies related to the changes measured during the study period. There is limited information for long-term outcomes, as the research focused on short-term symptom patterns rather than the prevention of recurrence or management of chronic conditions.

Research Considerations for H. pylori Eradication

This medicine was also evaluated in research exploring its role in multi-drug combination regimens for H. pylori infection, which is often associated with stomach ulcers. Research describing comparative data reported that outcomes monitored for the extended-release formulation were sometimes observed as lower in measurement compared to results related to the immediate-release form. Given this comparative data, evidence for the extended-release formulation in H. pylori treatment is limited and heterogeneous, particularly when compared to the established immediate-release standard.

Key Studies & References CLARITHROMYCIN tablet, film coated, extended release - Full Prescribing Information

How to Store and Dispose of Klaricid-OD?

Klaricid-OD (clarithromycin extended-release tablets) requires specific storage and handling to maintain its stability. The product must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F).

Storage Requirements

• Store the tablets in a tightly closed container in a cool, dry place.
• The medication must be protected from light.
• Always store the product out of the reach of children.

Disposal Instructions

• Remaining medication must be discarded after the treatment is complete.
• Disposal of unused or expired Klaricid-OD must comply with local regulations. Users should consult a pharmacy or medical institution if proper disposal methods are unknown.